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Abstract
Background: CD1d-restricted invariant NKT (iNKT) cells are a subset of T lymphocytes endowed with innate effector
functions that aid in the establishment of adaptive T and B cell immune responses. iNKT cells have been shown to play a
spontaneous protective role against experimental tumors. Yet, the interplay between iNKT and tumor-specific T cells in
cancer immune surveillance/editing has never been addressed. The transgenic adenocarcinoma of the mouse prostate
(TRAMP) is a realistic model of spontaneous oncogenesis, in which the tumor-specific cytotoxic T cell (CTL) response
undergoes full tolerance upon disease progression.
Principal Findings: We report here that lack of iNKT cells in TRAMP mice resulted in the appearance of more precocious and
aggressive tumors that significantly reduced animal survival. TRAMP mice bearing or lacking iNKT cells responded similarly
to a tumor-specific vaccination and developed tolerance to a tumor-associated antigen at comparable rate.
Conclusions: Hence, our data argue for a critical role of iNKT cells in the immune surveillance of carcinoma that is
independent of tumor-specific CTL.
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Introduction
Several lines of evidence in pre-clinical and clinical studies
support the notion that tumor cell growth is under the active
control of the immune system [1]. Cancer immune surveillance is
the result of concerted actions between innate and adaptive
immune responses [2]. T cell responses specific for tumor-
associated antigens (TAA) presented by MHC molecules on
cancer cells play a central role in cancer immune surveillance, and
can be increased by different immunotherapy strategies in
attempts to cure cancer [3].
iNKT cells are a subset of conserved T lymphocytes that bridge
innate and adaptive immunity [4]. They are characterized by the
expression of the homologous invariant (i)Va14-Ja18 and Va24-
Ja18 TCR chains in mice and humans, respectively [5,6]. The iVa
chains pair with a set of variable TCRb chains exhibiting a very
restricted Vb gene usage: Vb8.2, 7 and 2 in mice and Vb11 in
humans [4]. This semi-invariant TCR recognizes endogenous or
exogenous lipid antigens (Ag) presented by the MHC-class I like
molecule CD1d [7].
Unlike MHC-restricted T cells, iNKT cells exhibit an effector-
memory phenotype independently of foreign Ag encounter,
acquired in the thymus following a distinct developmental
pathway [8]. Injection into mice of the CD1d-restricted glyco-
sphingolipid Ag aGalactosylCeramide (aGalCer) potently acti-
vates iNKT cells, triggering within hours copious production of a
wide range of Th1 and Th2 cytokines [9]. These cytokines, in
turn, activate effector cells of both innate and adaptive immune
responses [9]. iNKT cell interaction with CD1d-expressing
immature dendritic cells (DC) results in the licensing of antigen
presenting functions, which facilitates priming of CD4
+ and CD8
+
T cell and B cell responses specific for concomitant protein Ag
[10,11]. Furthermore, cytokine production by iNKT cells can be
triggered independently of TCR engagement, for instance by the
action of inflammatory cytokines such as IL-12 and IL-18 [12].
Because of these peculiar innate-like effector characteristics,
iNKT cells are regarded as potent adjuvant involved in the early
activation of the immune response and in cancer immune
surveillance [13,14]. Consistent with this function, circulating
iNKT cell number have been found reduced in human solid
tumors, while IFN-c production and number of iNKT cells appear
to correlate with a more favorable prognosis in multiple myeloma,
colorectal cancer, head and neck cancer and prostate cancer (PC)
[15,16,17,18].
iNKT cell activation by aGalCer in vivo results in the subsequent
activation of NK and T cells, leading to the growth control of both
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[19,20,21].
iNKT cells display also a spontaneous anti-tumor function,
which occurs independently of aGalCer administration, possibly
induced by the recognition of endogenous lipid antigens. Mice
selectively deficient in iNKT cells (Ja18
2/2 mice) are in fact
significantly more susceptible to chemically induced carcinogenesis
[22]. In this model, adoptive cell transfer experiments established
that the protection from methylcholanthrene (MCA)-induced
fibrosarcoma is mediated by IFN-c-producing hepatic CD4
2
iNKT cells [23]. Furthermore, iNKT cells spontaneously suppress
the growth of osteosarcoma and hematopoietic tumors caused in
mice by the loss of the tumor suppressor p53 [24]. Because of the
lack of a traceable tumor Ag-specific T cell response in both MCA-
induced tumor models and in p53
+/2 mice, and development of
different and unpredictable tumor types in the latter, it is difficult
to correlate the presence or lack of iNKT with tumor-specific a
CTL response and its involvement in cancer immune surveillance.
Transgenic adenocarcinoma of the mouse prostate (TRAMP)
mice express the SV40 large T antigen (Tag) in the prostate
epitheliumunderthe control of theratprobasinregulatoryelement.
Sexual hormones influence the expression of the transgene [25];
hence, male mice remain healthy until puberty. In the following
weeks, TRAMP mice over-express Tag and invariably develop
spontaneous mouse prostate intraepithelial neoplasia (mPIN),
which progress to adenocarcinoma and seminal vesicles, lymph
node (LN) and visceral metastases, resembling human PC [26]. In
TRAMP mice, the immune response against the surrogate tissue-
specific TAA Tag is characterized by thymic deletion of high
avidity CTL [27]. As a consequence, vaccination with Tag-pulsed
DC in young healthy TRAMP mice elicits low avidity CTL specific
for the immunodominant sequence Tag404–411 (Tag-IV) [28]. In
parallel with PC development and progression, these CTL undergo
a profound state of peripheral tolerance [29] that cannot be rescued
by DC vaccination [29,30]. A similar phenomenon has been
reported in TRAMP mice for other surrogate [31] and natural
tumor associated antigens [32], and recapitulates the tolerant status
found in patients with advanced PC disease [33].
Given the data on anti-tumor roles of NKT cells in
transplantable and carcinogen tumor models together with the
clinical relevance of the TRAMP model, we investigated whether
iNKT cells control the growth of spontaneous PC, and whether
this phenomenon depends on the interplay between iNKT and
tumor-specific T cells.
Materials and Methods
Mice, Tumor Cell Lines and Reagents
Heterozygous TRAMP mice on a C57BL/6 background were
obtained from Dr. A Vitiello (The R.W. Johnson Pharmaceutical
Research Institute, San Diego, CA), originated from the founder
male 8247 [25], and were bred by crossing heterozygous TRAMP
females with wild type (WT) C57BL/6 males. B6.129-Tcra-Jtm1tg
mice Ja18-deficient (Ja18
2/2) were obtained from Dr. M.
Taniguchi (RIKEN, Yokohama, Japan) and backcrossed 12 times
to C57BL/6. TRAMPJa18
2/2 mice were generated at San
Raffaele by crossing TRAMP and C57BL/6 Ja18
2/2 mice.
Animals were typed for Tag expression by PCR-based screening
assay, as described in (www.jax.org). All mice were housed and bred
in a specific pathogen free animal facility. All procedures involving
animals were reviewed and approved by the Institutional Animal
Care and Use Committee at San Raffaele Scientific Institute.
Animals were monitored twice a week forweightandtumorgrowth,
and euthanized when signs of bulky prostate tumor and/or distress
were evident. RMA is a H-2
b Rauscher virus-induced thymoma
[34]. B6/K-0 is a kidney cell line, expressing Tag [35]. TRAMP-C1
is a PC cell line originated from a TRAMP mouse [36]. Unless
specified, all chemical reagents were from Sigma-Aldrich, and mAb
were from BD PharMingen (San Diego, CA).
DC Preparation and Immunization Protocols
DC were prepared and characterized as previously described
[37]. DC were pulsed with 2 mMT a g - I Vo r1mMt y r o s i n a s e
related protein 2 peptide181–200 (TRP-2; Research Genetics,
Huntsville, AL) for 1 h at 37uC, washed, and suspended at
1610
6/ml in PBS. Five610
5 DC were injected i.d. into mice.
When requested, aGalCer (100 ng/ml) was added to the DC
cultures 3 h before cell recovery. Magnetic-bead (Miltenyi
Biotec, Bologna, Italy) enriched CD8
+ splenocytes [38] from
mice euthanized one week after DC vaccination were stained
with PE-labeled K
b/Tag-IV or K
b/OVA (SIINFEKL) penta-
mers (ProImmune, Oxford, UK), CD8, CD44, and dump
(B220, CD11c, CD19, CD4) mAbs and analyzed by flow
cytometry [29]. For functional analysis of iNKT cells, aGalCer
(2 mg/mouse; Alexis, Lausen, Switzerland) was administered i.v.
Blood samples were collected from the tail vein 2, 6 and
24 hours later, and the serum content of IL-4 and IFN-c was
determined by standard ELISA (BD Pharmingen, San Diego,
CA). Animals were euthanized 72 hours after aGalCer treat-
ment, and the number of iNKT cells in their spleen and liver
was determined by staining with aGalCer-mCD1d tetramers
(provided by the NIH Tetramer Facility) and anti-TCRb mAbs
and flow cytometry analysis [39].
In Vitro Cytotoxicity Assay
Splenocytes were re-stimulated in vitro in the presence of 1 mM
Tag IV or TRP-2 peptide. Day-5-blasts were tested for cytolytic
activity in a standard 4 h
51Cr release assay [37].
51Cr release of
target cells alone was always ,25% of maximal
51Cr release
(target cells in 0.25 M SDS).
Histology and Immunohistochemistry
The urogenital apparatus (UGA) was excised, weighted, fixed in
4% formalin for 6 h, then embedded and included in paraffin wax.
H&E and Tag staining of 5-mm thick sections were performed as
previously described [30]. Macroscopic and microscopic speci-
mens were evaluated by a pathologist in a blind fashion. Histology
sections were scored as previously described [30,40] with partial
modifications: 0, healthy tissue; ,1, scattered (,20%) Tag
+ cells
with mild increase of nucleus to cytoplasm ratio; 1, $20% Tag
+
cells with increasing nucleus to cytoplasm ratio, nuclear hyper-
chromasia, stratification and micro-papillary projections; 2,
presence of all the features described in 1 and cribriform structures
with mild enlargement of acini; 3, presence of all the features
described in 2 and either proliferation of the epithelial and stromal
cells of the seminal vesicles or mild proliferation of smooth muscle
stromal cells of prostatic acini with acinar enlargement; 4,
presence of all the features described in 3 and marked proliferation
of smooth muscle stromal cells with penetration of malignant Tag
+
cells through the basement membrane of mPIN-involved glands
into the surrounding stroma; 5, well differentiated adenocarcino-
ma; and 6, presence of metastasis and/or neuroendocrine tumors.
Statistical Analysis
Statistical analyses were performed using the Student t-test, the
Log-Rank and the Mann-Whitney tests. Comparison of survival
curves was considered statistically significant for p,0.05.
NKT Cells and Prostate Cancer
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Survival of TRAMP Mice Lacking iNKT Cells Is Reduced
To investigate the role of iNKT cells in immune surveillance
against a spontaneous solid cancer, we generated male
TRAMPJa18
2/2 mice, and compared their survival with a
cohort of TRAMP mice. Animals were euthanized when signs of
bulky prostate tumor and/or distress were manifest. Anatomy and
histology of the UGA confirmed the presence of aggressive
prostate tumors in all animals (i.e., disease score $4; data not
shown). As reported in Fig. 1, TRAMPJa18
2/2 mice exhibited a
reduced disease-free survival, and all animals in this cohort were
euthanized before week 38. At this time, approximately 60% of the
TRAMP animals were still alive and apparently tumor free.
Comparison of survival curves of the two cohorts of mice revealed
a highly significant prolonged survival for TRAMP mice
(p,0.0001). Hence, the lack of iNKT cells appears to greatly
affect tumorigenesis in this model.
Tumor Onset Is Accelerated in TRAMP Mice Lacking iNKT
Cells
To better define the time of appearance and aggressiveness of
prostate tumors in TRAMPJa18
2/2 mice, cohorts of TRAMP
and TRAMPJa18
2/2 mice were sacrificed at different weeks after
birth and full autopsy was performed. Animals with bulky and
round-shaped prostate masses, which were histologically con-
firmed to be neuroendocrine prostate tumors, were excluded from
the study because appearance of these lesions is stochastic in
the TRAMP model [41]. Macroscopically, the UGA of
TRAMPJa18
2/2 mice appeared larger than that of age-matched
WT and even TRAMP males, with seminal vesicles particularly
engorged already at 17–18 weeks of age (data not shown). Indeed,
the UGA weight, an accepted parameter to measure disease
progression in this model, of TRAMP and TRAMPJa18
2/2
males was higher than that of age-matched WT mice at weeks 17–
24, and the difference further increased during the following weeks
(Fig. 2A; p,0.0001). Furthermore, a highly statistically significant
difference in UGA weight between TRAMPJa18
2/2 and WT or
TRAMP mice was present already at 12–16 weeks (p,0.0001),
time at which there was no difference in UGA weight between
TRAMP and WT males (Fig. 2A).
Difference in UGA weight was likely due to more advanced/
aggressive tumors and not to a generalized increase in body weight
of TRAMPJa18
2/2 mice. Indeed, when the ratio of the weight of
UGA and body weight subtracted of the UGA was calculated for
all groups of animals reported above (Fig. 2A), differences were all
confirmed (Fig. 2B).
Prostate tissues were also investigated microscopically. No
difference in disease score was present in TRAMP and
TRAMPJa18
2/2 mice at 6–8 weeks of age, and most of the
prostates at H&E staining showed scattered foci of cells with
nuclear elongation, altered nucleus-to-cytoplasm ratio and micro-
papillary projections, sometimes accompanied by cribriform
structures and mild enlargement of acini (data not shown).
Expression of Tag in 6–8 weeks old TRAMP mice and
TRAMPJa18
2/2 mice had a dim and patchy distribution
overlapping pathologic foci (data not shown), with, as expected
[30], a disease score,2 (Fig. 2C). In the following weeks, lesions in
TRAMPJa18
2/2 mice appeared more aggressive than that of age-
matched TRAMP animals, and the disease score was significantly
higher in TRAMPJa18
2/2 than in TRAMP animals at all weeks
tested (Fig. 2C).
Interestingly, invasive adenocarcinoma (disease score 5) was
found in 4 out of 13 (31%) TRAMPJa18
2/2 mice and in zero out
of 8 18–19 week old TRAMP mice. In the TRAMP colony
indeed, the earliest invasive adenocarcinoma was found at week
23. When cohorts of mice were sacrificed at week 25–28,
adenocarcinoma was found in 7 out of 11 (64%)
TRAMPJa18
2/2 mice versus 7 out of 46 (15%) TRAMP mice.
Hence, spontaneous PC development and progression, as
reported for tumors induced by MCA [22] or p53 loss [24], is
more aggressive in TRAMP mice lacking iNKT cells.
Similar Behavior of Tag-Specific CTL Responses in TRAMP
and TRAMPJa18
2/2 Mice
We next sought to investigate whether the iNKT cell-dependent
anti-tumor functions could be related to the induction and
maintenance of a spontaneous TAA-specific CTL response. The
low frequency of tumor-specific CTL in TRAMP mice precluded
the direct ex vivo comparison of frequency, phenotype and
functions in TRAMP and TRAMPJa18
2/2 mice [30]. However,
the detection ex vivo of tumor-specific CTL responses can be
achieved following in vivo expansion, obtained upon immunization
of TRAMP mice with specific TAA. By immunizing TRAMP
mice with DC pulsed with the TAA Tag, we were in fact able to
detect a specific CTL response. Furthermore, we previously
showed that PC growth is accompanied by the progressive
induction of a Tag-specific CTL tolerance that reaches a full state
at around 11 weeks of age [29,30].
To determine whether the precocious and more aggressive PC
found in TRAMPJa18
2/2 was due to the establishment of Tag-
specific CTL tolerance at an earlier stage than in TRAMP mice,
TRAMP, TRAMPJa18
2/2 and WT mice were immunized once
i.d. with Tag-IV pulsed DC at week 6–8, when tumor-specific
CTL are still functional, and sacrificed one week later. Ex vivo flow-
cytometry analysis showed a comparable frequency of
CD8
+CD44
+K
b/TagIV
+ cells in the spleen of vaccinated TRAMP
and TRAMPJa18
2/2 mice (0.960.14 and 1.3160.5%, respec-
tively), therefore indicating a similar in vivo expansion of Tag-
specific T cells in TRAMP and TRAMPJa18
2/2 mice.
Upon in vitro Ag-specific restimulation, splenocytes from
TRAMP and TRAMPJa18
2/2 demonstrated a comparable,
Figure 1. Survival of TRAMP mice lacking iNKT cells is reduced.
Kaplan-Maier plot reporting the survival curves of groups of male
TRAMP (black squares; n=21) and TRAMPJa18
2/2 mice (black circles;
n=21). Animals were examined twice a week and euthanized when
signs of bulky prostate tumor and/or distress were manifest. At
necropsy, the anatomy and histology of the UGA was analyzed as
indicated in the Material and Methods section. Animals were attributed
a disease score$4. Statistical comparison (Log-Rank test) between the
survival curves: p,0.0001.
doi:10.1371/journal.pone.0008646.g001
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RMA cells (Fig. 3A and B, respectively) that was, as expected [30],
lower than the one found in WT vaccinated mice (Fig. 3C). CTL
blasts efficiently killed also Tag
+ B6/K-0 targets (Fig. 3), therefore
demonstrating that these CTL were able to recognize the
endogenously processed and presented SV40 epitope. When
cohorts of TRAMP, TRAMPJa18
2/2 and WT males were
immunized after week 10, at which point, tumor-specific CTL
tolerance is full-blown [30], a Tag-specific immune response was
detected only in splenocytes from vaccinated WT animals (Fig. 3,
panels D, E and F, respectively), suggesting that tolerance of Tag-
specific CTL proceeded at comparable rates in TRAMP mice
bearing or lacking iNKT cells.
To investigate whether lack of immune response against Tag in
aged TRAMP and TRAMPJa18
2/2 mice reflected a generalized
immune suppression or was specific for the TAA, cohorts of
TRAMP, TRAMPJa18
2/2 and WT mice were immunized with
DC pulsed with the unrelated and K
b-restricted melanoma
antigen TRP-2. As reported in Fig. 4, all groups of mice generated
a comparable TRP-2-specific CTL response, therefore confirming
Figure 3. The immune response against Tag is comparable in
TRAMP and TRAMPJa18
2/2 mice. Tag-IV-pulsed DC were injected
once i.d. into 6- (panels A–C) and 16-week (D–F) old male TRAMP (A and
D), TRAMPJa18
2/2 (B and E) and WT age- and sex-matched littermates
(C and F). After 7 days, animals were killed and their splenocytes were
stimulated in vitro with irradiated B6/K-0 cells, and tested 5 days later
for cytotoxic activity (measured as
51Cr release); un-pulsed (black
squares) or Tag-IV-pulsed (black diamonds) RMA and B6/K-0 (black
circles) cells were used as targets. Data correspond to one out of at least
three independent experiments, which gave similar results.
doi:10.1371/journal.pone.0008646.g003
Figure 2. Tumor onset is accelerated in TRAMP mice lacking
iNKT cells. Age- and sex-matched male TRAMP (white bars; n=97),
TRAMPJa18
2/2 (black bars; n=51) and WT mice (gray bars; n=97) were
killed at the indicated week after birth and the anatomy and histology
of the UGA was analyzed as indicated in the Material and Methods
section. Animals affected by neuroendocrine tumors were excluded. A,
UGA weight (g), expressed as average6SEM, of TRAMP, TRAMPJa18
2/2
and WT mice killed at weeks 6–8 (n=5, 8 and 19, respectively), 12–16
(n=16, 17 and 26), 17–24 (n=30, 15 and 26) and 25–28 (n=46, 11 and
26), respectively. B, ratio of the weight of UGA and body weight
subtracted of the UGA in the groups of animals reported above. C,
Disease score, expressed as average6SEM, of the groups of animals
reported above. Statistical analysis of collected data was performed
using the Student’s t-test (A and B) and the Mann-Whitney test (C);
***p,0.001, **0.001,p,0.05, *0.01,p,0.05.
doi:10.1371/journal.pone.0008646.g002
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2/2 mice is restricted
to the PC-associated antigen.
Since it has been reported that immunization of mice with the
iNKT cell strong agonist antigen aGalCer enhances the T cell
response specific for a concomitantly administered antigen, mainly
via the NKT cell-mediated licensing of DC function [10], we
investigated whether the presence of aGalCer on DC could break
Tag-specific CTL tolerance in TRAMP mice. As a preliminary
experiment, we compared the functional activity of iNKT cells both
in TRAMP and WT C57BL/6 male mice by determining the
systemic release of IL-4 and IFNc after injection of aGalCer i.v. As
expected, IL-4 and IFNc concentration in the serum peaked at 2
and 6 hours after aGalCer injection (Fig. 5), with no statistically
significant differences between TRAMP and WT C57BL/6 mice.
Furthermore, both frequency and absolute number of splenic and
hepatic iNKT cells, determined by aGalCer-mCD1d tetramer
staining, were also comparable between the two strain of mice (data
not shown). We then immunized fifteen week-old TRAMP mice
with DC pulsed either with Tag-IV and aGalCer or with Tag-IV
alone. One week later, the presence of Tag-specific CTL in the
immunized mice was determined by in vitro restimulation of spleen
cells with the TAA. A Tag-specific CTL response, however, could
not be found in either group of vaccinated mice (data not shown).
Taken together, these data suggest that Tag-specific peripheral
CTL tolerance, induced by PC development and progression, is
not influenced by iNKT cells, and that iNKT cells exert an as yet
undefined role in PC immune surveillance in TRAMP mice.
Discussion
This study demonstrates that iNKT cells play a relevant role in
the immune surveillance of spontaneous prostate adenocarcinoma
in TRAMP mice, extending substantially the findings that these
cells suppress the onset of spontaneous sarcomas and hematopoi-
etic malignanices [24]. The observation that the lack of iNKT cells
correlates with a more aggressive disease in TRAMP mice is
consistent with the findings showing that the progression of
different types of human cancers, including PC, is accompanied by
a significant decrease in iNKT cell number [15,16,17,18]. Thus,
iNKT cells appear to play an active role both in mice and in
humans in controlling different forms of cancer, ranging from
hematological malignancies to sarcoma and carcinoma, arguing
for an unconstrained capacity of these cells to survey transformed
cells in multiple organs and tissues, through as yet unrecognized
mechanisms. Furthermore, our results underscore the relevance of
the TRAMP model for deciphering the mechanisms by which the
immune system controls solid tumor outgrowth.
iNKT cells display a powerful helper activity for adaptive T as
well as B cell responses, exerted mainly via enhancing antigen
presenting functions in DC [10,11], which result in facilitated
priming of peptide-specific CD4
+ and CD8
+ T cell responses.
Figure 4. Tolerance in tumor-bearing mice is specific for the
PC-related Ag Tag. TRP-2-pulsed DC were injected once i.d. into 16-
week old male TRAMP (left panel), TRAMPJa18
2/2 (middle panel) and
WT age- and sex-matched littermates (right panel). After 7 days, animals
were killed and their splenocytes were stimulated in vitro with the TRP-2
peptide, and tested 5 days later for cytotoxic activity (measured as
51Cr
release); un-pulsed (black diamonds) or TRP-2-pulsed (black triangles)
RMA cells were used as targets. Each panel is representative of at least
two independent experiments.
doi:10.1371/journal.pone.0008646.g004
Figure 5. aGal-Cer-mediated release of iNKT-associated cyto-
kines. aGalCer (2 mg/mouse) was administered i.v. to TRAMP (white
circles) and WT (black circles) littermates, and blood samples were
collectedfromthetail vein 2,6 and24 hours later,andthe serumcontent
of IL-4 and IFN-c was determined by standard ELISA. Values are reported
as concentration of the cytokine (pg/ml) in the sera of each animal (3–4/
experimental group) analyzed at the indicated time points. Reported
data are representative of at least two independent experiments.
doi:10.1371/journal.pone.0008646.g005
NKT Cells and Prostate Cancer
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of influenza A virus–induced Gr1
+CD11b
+/CD15
+CD11b
+
myeloid precursors in mice and humans, respectively, by
promoting their maturation into functional DC [42]. Given that
Gr1
+CD11b
+ myeloid precursors share phenotypic and functional
characteristics with myeloid-derived suppressor cells (MDSC) [43],
iNKT cells might exert their anti-tumor effector functions via
modulation of MDSC activity, resulting in a reduced suppression
of tumor-specific T cell responses [44]. Such mechanisms could
enhance tumor-specific T cell response as well. However, such
Gr1
+CD11b
+ cells appear defective and may actually suppress
iNKT cells in tumor-bearing animals [45]
We did not find evidence that supports a correlation between
the presence of iNKT cells in TRAMP mice and either the
efficiency of the Tag-specific CTL response or a decreased
induction of tolerance toward Tag. Indeed, Tag-specific tolerance
appeared at similar rates in TRAMP and TRAMPJa18
2/2 mice,
and could not be broken by immunization with DC pulsed with
Tag-IV plus aGalCer. Moreover, we have found that the
frequency and function of MDSC as well as CD4
+CD25
+Foxp3
+
regulatory T cells [46] are similar in TRAMP [[29] and Capuano
G. et al., manuscript in preparation] and TRAMPJa18
2/2 mice
(data not shown), suggesting that a direct cross-talk between iNKT
cells and MDSC or regulatory T cells is not a relevant mechanism
in TRAMP mice. Altogether, these data provide indirect evidence
that iNKT cells are not involved in controlling the induction of
CTL tolerance in TRAMP mice and, consequently, the anti-
tumor effector T cell response.
Studies performed in vitro have shown that human iNKT can be
directly cytotoxic against CD1d
+ tumor cell targets. The
expression of CD1d has been detected on some types of primary
human leukemia blasts [47] and on glioma cells [48]. However,
the expression of CD1d on mouse tumor cells seems more frequent
[49] and our preliminary data suggest that mouse primary PC cells
from TRAMP mice express CD1d (data not shown). Nevertheless,
it should be taken into consideration that in the absence of strong
exogenous ligands such as aGalCer, iNKT exhibit little cytotoxic
activity against CD1d
+ mouse and human tumor cells [47,50].
Therefore, whether iNKT cells can directly kill tumor cells in vivo
remains to be established. Interestingly, in this context, human
iNKT cells can kill macrophages that are supposed to infiltrate
human neuroblastoma in a CD1d-dependent manner [51],
providing a mechanistic link between neuroblastoma infiltration
by iNKT cells and an improved prognosis [51]. We can therefore
speculate that mouse iNKT cells may control PC growth in
TRAMP mice by limiting the number or altering the function of
tumor associated macrophages (TAM), which play an important
role in supporting neoangiogenesis and tumor growth [52] via
IFN-c production.
The definition of the mechanism by which iNKT cells control
mouse PC growth warrants future investigation.
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